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A BRCA1 Nonsense Mutation Causes Exon Skipping
To the Editor:
Nonsense mutations can induce the skipping of consti-
tutive exons, as has been shown in a few disease-causing
genes (Dietz et al. 1993; Gibson et al. 1993; Naylor et
al. 1993; Hull et al. 1994; Santisteban et al. 1995; Pie´
et al. 1997). Shortened translational reading frames are
also sometimes associated with a reduction in mRNA
abundance (Maquat 1996). However, few of the pre-
mature-termination codons involved in genetic diseases
have been comprehensively assayed for induced tran-
script defects.
The BRCA1 gene, located on chromosome band
17q21, has a coding sequence of 5,592 nucleotides scat-
tered on 22 exons (Miki et al. 1994). Germ-line muta-
tions in this gene lead to the predisposition to breast
and ovarian cancer. More than 1,250 different mutations
of the BRCA1 gene have been reported worldwide,
spread over the entire length of the gene (Breast Cancer
Information Core 1997 [http://www.nhgri.nih.gov/
Intramuralresearch/Labtransfer/Bic/]); most of them
lead to premature-termination codons, as a result of
frameshift, nonsense, or splice-site mutations (Couch et
al. 1996) or large rearrangements (Puget et al. 1997;
Swensen et al. 1997). Most mutation-screening studies
are conducted on genomic DNA only, and, as yet, little
effort has been made to check for possible induced tran-
script defects. By contrast, evaluation of the phenotypic
risk associated with mutations has received a great deal
of attention because it is very important in genetic coun-
seling. A correlation between the location of the mu-
tation in the BRCA1 gene and the ratio of the incidence
of breast to ovarian cancer has been shown (Gayther et
al. 1995; Shattuck-Eidens et al. 1995). However, such a
trend has not been found systematically. The reason may
be that taking into account the location of the mutation
rather than its consequences at the level of the transcript
could be misleading in such studies, because it is im-
possible to predict which premature stop codon will lead
to a reduction in mRNA abundance or to exon skipping.
We describe here, for the first time, nonsense-mediated
exon skipping in the BRCA1 gene, in one breast and
ovarian cancer family (number 3497), recruited by Dr.
H. Lynch at Creighton University, Omaha, that contains
four breast and four ovarian cancer cases (among which
are one case of bilateral breast cancer and one case of
bilateral breast cancer and ovarian cancer). A fragment
of BRCA1 cDNA covering exons 16–22 was shown to
produce, after amplification by PCR and migration on
an agarose gel, two bands of equal intensity in affected
family members, one of the expected size (596 bp) and
one slightly smaller. Simultaneous direct sequencing of
both templates demonstrated a 78-bp in-frame deletion
in the smaller fragment corresponding to the entire exon
18. Alternative splicing removing exon 18 does not occur
naturally (Xu et al. 1997; authors’ unpublished data).
In order to identify the basis of exon skipping, we am-
plified, by PCR, a 352-bp fragment from genomic DNA
encompassing 78 bp of intron 17, all of exon 18, and
196 bp of intron 19. We observed no mutation in all
the cis-acting consensus elements known to be involved
in RNA splicing (i.e., the 3′ and 5′ splice sites and the
predicted branchpoint flanking exon 18: TTCTAAT at
positions 31 to 25). However, a GrT substitution
was found in exon 18 at nucleotide 5199 (codon 1694),
which changes a glutamic acid to a stop codon
(Glu1694ter). To find out whether any transcript with
exon 18 containing the stop codon was expressed, we
specifically amplified from cDNA a fragment with prim-
ers in exons 16 and 18 (thereby preventing amplification
from the transcript without exon 18), which was then
sequenced. Only a wild-type exon 18 sequence was
found in all carriers, which implies that the mutant allele
produces only mRNA in which exon 18 had been
skipped.
Although the Glu1694ter mutation would be expected
to lead to the truncation of 169 amino acids from the
BRCA1 protein, the skipping of the in-frame exon 18
removes 26 amino acids (Asp1692–Phe1717). Never-
theless, it leads to the disruption of the first BRCT do-
main, since it removes part of block D, the most highly
conserved motif within this domain (Callebaut and Mor-
non 1997). The block D motif is organized around a
conserved aromatic residue. In the case of BRCA1, this
residue is Trp, which is changed to Gly because of the
junction of exon 17 to exon 19. It is therefore unlikely
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that the mutant BRCA1 protein would remain totally
functional.
In at least two cases of nonsense-mediated exon skip-
ping (Santisteban et al. 1995; Pie´ et al. 1997), the mu-
tation was found to be located in a purine-rich sequence
that could function as an exonic splicing enhancer (ESE),
thereby impairing its function. These ESE sequences
have been shown to affect the selection of the splice sites
(Cooper and Mattox 1997). In the case of Glu1694ter
in BRCA1 exon 18, exon skipping is probably not the
result of the inactivation of an ESE, since the GrT sub-
stitution does not take place in a purine-rich sequence.
It has also been proposed that point mutations in an
exon could lead to disruption of secondary structure,
with consequent aberrations in RNA splicing. We cannot
exclude a structural effect of Glu1694ter on the splicing
of BRCA1 exon 18, the mutation occurring only six
nucleotides downstream of the intron 17 splice acceptor.
By contrast, experimental data suggest that maintenance
of an open reading frame can serve as an additional level
of scrutiny during exon definition; nonsense codons
could thus directly alter splice-site selection (Dietz and
Kendzior 1994). Additional work is needed to better
identify the relevant mechanism and machinery that
evaluate the coding potential of nuclear pre-mRNAs.
Glu1694ter has already been reported four times
(Breast Cancer Information Core 1997 [http://www.
nhgri.nih.gov/Intramuralresearch/Labtransfer/Bic/]),
but on genomic DNA, so the skipping of exon 18 re-
sulting from this mutation has probably been missed.
Clearly, it would be interesting to investigate the con-
sequence of each BRCA1 mutation, found using ge-
nomic DNA, at the cDNA level. In addition to the fun-
damental aspect of finding the mutation, these findings
could have implications to draw a genotype-phenotype
correlation.
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